Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

17.69USD
11:23am EDT
Change (% chg)

$0.09 (+0.51%)
Prev Close
$17.60
Open
$17.69
Day's High
$17.81
Day's Low
$17.49
Volume
14,311
Avg. Vol
88,818
52-wk High
$32.54
52-wk Low
$14.36

Latest Key Developments (Source: Significant Developments)

Macrogenics announces termination of duvortuxizumab collaboration
Thursday, 31 Aug 2017 04:30pm EDT 

Aug 31 (Reuters) - Macrogenics Inc ::Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen.Macrogenics Inc - ‍enrollment of phase 1 dose-escalation study of this molecule is being discontinued​.Macrogenics Inc - ‍Janssen has indicated that it anticipates initiating a first-in-human study with molecule in 2018​.Macrogenics Inc - ‍Janssen reaffirmed its commitment to MGD015, also known as JNJ-9383, a second dart molecule licensed from Macrogenics​.Macrogenics Inc - ‍Janssen is terminating collaboration and license agreement with Macrogenics relating to duvortuxizumab, a CD19 X CD3 dart molecule​.Macrogenics Inc - ‍unlikely that co will continue development of duvortuxizumab, a CD19 X CD3 dart molecule "at this time​".  Full Article

Macrogenics Inc enters into sales agreement with Cowen and Company
Friday, 5 May 2017 08:55am EDT 

May 5 (Reuters) - Macrogenics Inc : :Macrogenics Inc says on May 3, 2017, company entered into sales agreement with Cowen and Company LLC .Macrogenics Inc says may sell shares of company's common stock, aggregate offering price of up to $75.0 million through Cowen and Co.  Full Article

Macrogenics announces registered direct offering of common stock
Thursday, 27 Apr 2017 07:00am EDT 

April 27 (Reuters) - Macrogenics Inc ::Macrogenics announces registered direct offering of common stock.Macrogenics - definitive agreement with institutional healthcare investor to purchase 1.1 million shares of stock at purchase price of $21.50/share.Macrogenics Inc- gross proceeds to macrogenics, before deducting estimated offering expenses, will be $23.65 million.Macrogenics Inc- shares were offered pursuant to company's shelf registration and offering is expected to close on or about May 2, 2017.  Full Article

Macrogenics provides announces 2016 financial results
Tuesday, 28 Feb 2017 04:01pm EST 

Macrogenics Inc : Macrogenics provides update on corporate progress and 2016 financial results .Macrogenics - expects its current cash, cash equivalents, anticipated funding under current collaborations, should fund co's operations through late 2018.  Full Article

First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics
Tuesday, 10 May 2016 07:30am EDT 

MacroGenics Inc : Commencement of phase 1 study triggers a $2 million milestone payment to MacroGenics under companies' October 2010 agreement. . Pfizer recently dosed a first patient in phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3 .First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics.  Full Article

MacroGenics Inc and Merck to collaborate on Immuno-Oncology study
Thursday, 22 Oct 2015 07:30am EDT 

MacroGenics Inc and Merck:Says collaboration to evaluate the combination of MacroGenics' anti-HER2 product candidate, margetuximab, with Merck's anti-PD-1 therapy, KEYTRUDA, in a Phase 1b/2 clinical trial in patients with advanced gastric cancer.Says agreement is between MacroGenics and Merck, through a subsidiary.Additional details were not disclosed.  Full Article

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules